Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Bought by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB raised its holdings in Scholar Rock Holding Co. (NASDAQ:SRRK) by 6.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 57,185 shares of the company’s stock after acquiring an additional 3,685 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Scholar Rock were worth $1,838,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of SRRK. Global Retirement Partners LLC lifted its holdings in Scholar Rock by 584.7% in the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock valued at $39,000 after acquiring an additional 766 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Scholar Rock during the fourth quarter valued at about $85,000. Amalgamated Bank lifted its stake in Scholar Rock by 30.6% during the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock valued at $114,000 after buying an additional 620 shares in the last quarter. KBC Group NV purchased a new stake in shares of Scholar Rock in the fourth quarter worth approximately $131,000. Finally, NEOS Investment Management LLC purchased a new stake in shares of Scholar Rock in the fourth quarter worth approximately $209,000. 91.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Wedbush reissued an “outperform” rating and issued a $50.00 price target on shares of Scholar Rock in a research report on Wednesday, May 14th. Lifesci Capital upgraded Scholar Rock to a “strong-buy” rating in a report on Tuesday. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $42.67.

Insider Transactions at Scholar Rock

In other news, insider Akshay Vaishnaw sold 6,750 shares of the business’s stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $29.72, for a total transaction of $200,610.00. Following the completion of the transaction, the insider now directly owns 616,205 shares in the company, valued at approximately $18,313,612.60. The trade was a 1.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Edward H. Myles sold 142,292 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $35.62, for a total value of $5,068,441.04. Following the transaction, the chief financial officer now owns 111,345 shares of the company’s stock, valued at $3,966,108.90. The trade was a 56.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 181,798 shares of company stock worth $6,284,738. 13.30% of the stock is currently owned by company insiders.

Scholar Rock Stock Down 0.1%

Shares of NASDAQ SRRK opened at $34.23 on Friday. Scholar Rock Holding Co. has a 52-week low of $6.76 and a 52-week high of $46.98. The stock has a market cap of $3.25 billion, a PE ratio of -14.57 and a beta of 0.37. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The business has a fifty day moving average of $30.37 and a two-hundred day moving average of $36.15.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.04). During the same period in the previous year, the business posted ($0.59) earnings per share. As a group, equities research analysts expect that Scholar Rock Holding Co. will post -2.42 earnings per share for the current fiscal year.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.